The Chicago Lung Run is held each year in support of lung cancer survivors and their families, and in memory of those who have lost their lives to lung cancer, the leading cancer killer in America. The mission of the Chicago Lung Run is to raise awareness of lung cancer and to raise much-needed funds for lung cancer research.
The 2010 Chicago Lung Run will benefit cutting-edge lung cancer research through:
The mission of Respiratory Health Association of Metropolitan Chicago is to promote healthy lungs and fight lung disease through research, education and advocacy. RHAMC has been a leading lung health advocate since 1906. From its crusade against TB in the early 1900's to today's groundbreaking programs in women's lung health, asthma, COPD and lung cancer, RHAMC has been in the forefront of Chicago's fight against lung disease. Enlisting the finest educational tools from across the nation, RHAMC offers tobacco cessation and asthma education programs targeting adults, caregivers and children. A strong local advocacy effort culminated in the passage of smoke-free legislation in Chicago and Illinois, and limitations on power plant emissions. Respiratory Health Association has been a local leader in securing funding for important lung health research projects at Chicago area universities and serves as host to Chicago Thoracic Society, the local presence of American Thoracic Society in metropolitan Chicago. Funds raised through the 2008 Lung Run will support important lung cancer research projects through RHAMC.
Uniting Against Lung Cancer is a nonprofit 501 (c) (3) organization committed to fight lung cancer by funding innovative research into the diagnosis and treatment of the disease, including those who never smoked. Since 2003 over $6 Million has been awarded through 60 research grants to individual researchers at top cancer centers in 21 states.
Your Donations at Work
Proceeds from the Chicago Lung Run are funding important research projects around the country. For example, the 2009 race helped fund the following research:
Serum proteomics on patients treated with erlotinib
Mary Jo Fidler, MD; Rush University Medical Center
Non-small cell lung cancer (NSCLC) is one of 2 types of lung cancer. It accounts for 85 – 90% of all lung cancers. People diagnosed with NSCLC may respond differently to different types of treatment for NSCLC. Dr. Fidler seeks to identify biomarkers, or molecules, in cells and fluids that can help predict an individual’s response to a certain treatment for NSCLC. Ultimately, this research will help the medical community treat NSCLC more effectively.
Proteomic Analysis of Serum and Tumor Tissue in Small Cell Lung Cancer
Marta Batus, MD; Rush University Medical Center
Small cell lung cancer (SCLC) is one of 2 types of lung cancer, and about 10-15% of all lung cancers are SCLC. Dr. Batus is studying molecules found in blood and tissue (called biomarkers) that are associated with SCLC. Specifically, Dr. Batus’ research aims to identify: 1) biomarkers that are characteristic of small cell lung cancer; 2) biomarkers that will predict response to chemotherapy and resistance to treatment for SCLC; 3) biomarkers that will predict survival in SCLC; and 4) biomarkers that predict the likelihood of the SCLC spreading to the brain. This research will ultimately help the medical community detect and treat SCLC more effectively.
The 2008 race helped fund the Lung Cancer Promise Award, a two-year $200,000 award, which was granted to Dr. Navdeep Chandel, Assistant Professor of Medicine at Northwestern University’s Feinberg School of Medicine. Dr. Chandel’s research looks at cellular signaling and how it may lead to the development of adenocarcinoma, a type of non-small cell lung cancer accounting for 30% of all non-small cell cases. Understanding how this signaling system works in the cells may eventually lead to the development of new therapies to treat and prevent adenocarcinoma.
Additional funding partners on this award include: Breathe New Hampshire, Breathe California of the Bay Area, Breathe California of Los Angeles County, the Arkansas Respiratory Health Association, and LUNGevity Foundation.
Proceeds from the 2008 Chicago Lung Run also benefited the research of Dr. Ravi Salgia, Professor of Medicine and Director of the Thoracic Oncology Research Program at The University of Chicago Medical Center.
Adenocarcinoma is a type of non small cell lung cancer, and is the most common type of lung cancer in non-smokers. Dr. Ravi Salgia’s research involves studying the biomarkers in tumor and blood of women who smoke and women who don’t smoke with adenocarcinoma. This highly innovative research will provide insight into developing a blood test for adenocarcinoma in women, as well as provide some insight into the genes that may involved.
The Chicago Lung Run was started in loving memory of Fred Huetter, Joanne Juscik, and William Moran.